40 OF 50 CAPLUS COPYRIGHT 2003 ACS on STN

Full Text | Citing References

AN 1995:785110 CAPLUS
DN 123:160827
TI Use of N-alkyl derivatives of 1,5-dideoxy-1,5-imino-D-glucitol for the treatment of **hepatitis** B virus infections
IN Block, Timothy M.; Blumberg, Baruch S.; Dwek, Raymond A.
PA G.D. Searle and Co., USA; Monsanto Co.
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9519172	A1	19950720	WO 1994-US14548	19941223
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2181033	AA	19950720	CA 1994-2181033	19941223
	AU 9514037	A1	19950801	AU 1995-14037	19941223
	EP 739205	A1	19961030	EP 1995-905416	19941223
	EP 739205	B1	19991124		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1149253	A	19970507	CN 1994-195049	19941223
	CN 1074921	B	20011121		
	JP 09508111	T2	19970819	JP 1994-519024	19941223
	AT 186836	E	19991215	AT 1995-905416	19941223
	ES 2140652	T3	20000301	ES 1995-905416	19941223
	US 6037351	A	20000314	US 1996-676153	19960711
PRAI	US 1994-181519	A	19940113		
	WO 1994-US14548	W	19941223		

AB A method is disclosed for the treatment of **hepatitis** B virus (HBV) infections, which comprises administering to the infected host an N-alkyl deriv. of 1,5-dideoxy-1,5-imido-D-glucitol in which the alkyl group contains from 3 to 6 carbon atoms. In examples, N-butyl-1,5-dideoxy-1,5-imino-D-glucitol was shown to suppress the secretion of HBV particles and to cause intracellular retention of HBV DNA in both stably transfected HepG 2.2.15 cells and HBV-infected HepG 2 cells.

IT **72599-27-0**, N-Butyl 1-deoxynojirimycin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(deoxynojirimycin alkyl derivs. for treatment of **hepatitis** B virus infections)

RN 72599-27-0 CAPLUS
CN 3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R,3R,4R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

	CA 2319713	AA	19990819	CA 1999-2319713	19990212
	AU 9927595	A1	19990830	AU 1999-27595	19990212
	AU 762125	B2	20030619		
	ZA 9901142	A	20000214	ZA 1999-1142	19990212
	BR 9907882	A	20001017	BR 1999-7882	19990212
	EP 1061922	A1	20001227	EP 1999-908079	19990212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2002502875	T2	20020129	JP 2000-531168	19990212
PRAI	US 1998-23401	A	19980212		
	US 1998-74508P	P	19980212		
	US 1997-41221P	P	19970214		
	WO 1999-US1874	W	19990212		

OS MARPAT 131:165293

AB Methods and compns. are provided for treating **hepatitis** virus infections in mammals, esp. humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compds. alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixts. thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compds. alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixts. thereof, and immunomodulating/immunostimulating agents.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

L8 ANSWER 33 OF 50 CAPLUS COPYRIGHT 2003 ACS on STN

Full Text | Citing References

AN 2000:172843 CAPLUS
DN 132:175813
TI Method using an N-alkyl derivative of 1,5-dideoxy-1,5-imino-D-glucitol for inhibiting **hepatitis** B virus
IN Block, Timothy M.; Blumberg, Baruch S.; Dwek, Raymond A.
PA G. D. Searle & Co., USA
SO U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 181,519, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6037351	A	20000314	US 1996-676153	19960711
	WO 9519172	A1	19950720	WO 1994-US14548	19941223

W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

PRAI	US 1994-181519	B2	19940113
	WO 1994-US14548	W	19941223

AB A method is disclosed for the treatment of **hepatitis** B virus (HBV) infections which comprises administering to the infected host an N-alkyl deriv. of 1,5-dideoxy-1,5-imino-D-glucitol in which the alkyl group contains from 3 to 6 carbon atoms.
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 35 OF 50 CAPLUS COPYRIGHT 2003 ACS on STN

Full Text | Citing References

AN 1999:529023 CAPLUS
DN 131:165293
TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating **hepatitis** virus infections
IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.
PA G.D. Searle & Co., USA
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940916	A1	19990819	WO 1999-US1874	19990212

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	US 2003100532	A1	20030529	US 1998-23401	19980212

AB The effects were studied of tunicamycin and inhibitors of the processing of N-linked glycans, including N-methyl-1-deoxynojirimycin, castanospermine, mannodeoxynojirimycin, and swainsonine, on the transport of glycoprotein E2 and the intracellular maturation of the coronavirus mouse **hepatitis** virus A59. Indirect immunofluorescence staining with monoclonal antibodies revealed that glycoprotein E2 exhibits different antigenic properties depending on the presence and the structure of the N-linked oligosaccharides and that efficient transport of glycoprotein E2 to the plasma membrane requires the removal of glucose residues. In the presence of tunicamycin, the nonglycosylated E2 apoprotein was synthesized in normal amts. and readily acylated throughout the infectious cycle. This E2 species could not be detected on the surface of mouse **hepatitis** virus A59-infected cells with indirect immunofluorescence staining or lactoperoxidase labeling. N-Methyl-1-deoxynojirimycin and catanospermine, both of which selectively inhibited the processing glucosidases, caused a drop in virion formation by 2 log steps and a drastic delay in the surface expression of glycoprotein E2. The E2 species synthesized under such conditions was acylated but accumulated intracellularly in a compartment distinct from the Golgi. Concomitantly, synthesis of the matrix glycoprotein E1 of mouse **hepatitis** virus A59 was drastically impaired. Mannodeoxynojirimycin and swainsonine, which block later stages of the processing pathway, had less or no effect on the transport of glycoprotein E2 and formation of virus particles.

IT 69567-10-8
RL: BIOL (Biological study)
(glycoprotein E2 of mouse **hepatitis** virus intracellular migration response to)

RN 69567-10-8 CAPLUS

CN 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-1-methyl-, (2R,3R,4R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>



L8 ANSWER 41 OF 50 CAPLUS COPYRIGHT 2003 ACS on STN

Full Text | Citing References

AN 1994:671340 CAPLUS
DN 121:271340
TI N-Butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. Secretion of human **hepatitis** B virus is inhibited by the imino sugar N-butyldeoxynojirimycin
AU Ganem, Bruce
CS Cornell Univ., USA
SO Chemtracts: Organic Chemistry (1994), 7(2), 106-7
CODEN: CMOCEI; ISSN: 0895-4445
DT Journal
LA English
AB N-butyldeoxynojirimycin inhibited the biosynthesis of glycolipids and treated cells infected with **hepatitis** B virus.
IT 72599-27-0, N-Butyldeoxynojirimycin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(butyldeoxynojirimycin inhibition of glycolipid biosynthesis and human **hepatitis** B virus)
RN 72599-27-0 CAPLUS
CN 3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R,3R,4R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 50 OF 50 CAPLUS COPYRIGHT 2003 ACS on STN

Full Text | Citing References

AN 1985:592966 CAPLUS
DN 103:192966
TI The effects of processing inhibitors of N-linked oligosaccharides on the intracellular migration of glycoprotein E2 of mouse **hepatitis** virus and the maturation of coronavirus particles
AU Repp, Reinald; Tamura, Teruko; Boschek, C. Bruce; Wege, H.; Schwarz, Ralph T.; Niemann, Heiner
CS Inst. Med. Virol., Justus-Liebig-Univ., Giessen, D-6300, Fed. Rep. Ger.
SO Journal of Biological Chemistry (1985), 260(29), 15873-9
CODEN: JBCHA3; ISSN: 0021-9258
DT Journal
LA English